A5012467418- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Ferroptosis and cancer prognosis
- BRCA gene mutations in cancer
- Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Estrogen and related hormone effects
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Platelet Disorders and Treatments
- Acute Myeloid Leukemia Research
- Antiplatelet Therapy and Cardiovascular Diseases
- Cancer Risks and Factors
- Polyomavirus and related diseases
- Renal Transplantation Outcomes and Treatments
- Sarcoma Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Intramuscular injections and effects
- Complement system in diseases
- Bioinformatics and Genomic Networks
- Hematopoietic Stem Cell Transplantation
- COVID-19 and healthcare impacts
- Computational Drug Discovery Methods
- Heparin-Induced Thrombocytopenia and Thrombosis
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
Winthrop-University Hospital
2010-2022
Island Hospital
2021-2022
NYU Langone Health
2022
Long Island University
2022
NYU Langone’s Laura and Isaac Perlmutter Cancer Center
2021
Stony Brook School
2013
Stony Brook University
2013
Drexel University
2007
Hahnemann University Hospital
2007
1513 Background: In high-risk estrogen-receptor positive, HER2 or triple negative breast cancer (BC), chemotherapy can increase cure rates in early-stage disease and prolong survival setting of advanced disease. Real world data specific to BC is needed counsel patients (pts) with on their risk for SARS-CoV-2 infection mortality the context pandemic. Methods: this retrospective study, we abstracted clinical including demographics, tumor histology, treatment, COVID-19 testing results status...
Women diagnosed under the age 45 and within 5-10 years of a childbirth have increased risk metastasis. These high-risk cancers, defined as post-partum breast cancer (PPBC), significantly worse prognosis independent clinical-pathologic features demonstrate treatment resistance. We hypothesized that PPBC exhibits high molecular profile sought to define genomic patterns PPBC. The prospective, observational FLEX Study (NCT03053193) includes stage I-III early BC patients who received...
TPS7088 Background: Genomic expression profiles have enabled the classification of breast cancers into molecular sub-types and provide prognostic information about metastatic potential tumor, both which implications for personalized treatment cancer beyond clinical pathological features. However, to precisely stratify tumors actionable subgroups, full genome data should be combined with comprehensive information. The FLEX Registry aims aggregate a large, real-world dataset, will enable...
Abstract Purpose Provide real-world data regarding the risk for SARS-CoV-2 infection and mortality in breast cancer (BC) patients on active treatment. Methods Clinical were abstracted from 3778 BC seen at a multisite center New York between February 1, 2020 May 2020, including patient demographics, tumor histology, treatment, testing results. Incidence of by treatment type (chemotherapy [CT] vs endocrine and/or HER2 directed therapy [E/H]) was compared Inverse Probability Treatment...
Abstract Background: Neoadjuvant endocrine therapy (NET) has long been limited to patients who were deemed medically unfit for immediate surgery or on clinical trials. Coronavirus disease 2019 (COVID-19) resulted in a global pandemic, which led deferral of elective surgeries including breast early stage cancer during March - June 2020. Institutional guidelines developed based societal recommendations, NCCN, use NET as bridge surgery. Objective: Primary objective was establish database HR+...
560 Background: Genomic tests provide critical information regarding risk of recurrence and inform treatment plans by identifying those patients who may safely forgo chemotherapy (CT) or shorten endocrine therapy (ET) duration. The IMPACT trial demonstrated that the 70 -gene assay MammaPrint (MP) 80-gene subtyping BluePrint (BP) planning increase physician confidence. However, not all genomic yield same results. To examine consistency among tests, we analyzed implications for received...
565 Background: Recent prospective clinical trials have demonstrated a differential chemotherapy effect based on age (≤ 50 vs. > years) or menopausal status (pre- post-) in genomic low risk group. Whether this is direct anti-tumor of secondary ovarian function suppression caused by unclear. We aimed to compare the biological characteristics breast cancer tumors from patients aged ≤ years and using whole transcriptome analysis provide insights into response. Methods: The FLEX Registry...
Abstract Background: Genomic expression profiling has significantly improved the personalized treatment of breast cancer, by providing prognostic information about metastatic potential tumors and enabling classification cancers into molecular subtypes, beyond clinical pathological factors. When combined with comprehensive data, full genome data can precisely stratify clinically actionable subgroups. The FLEX Study is aggregating a large, real-world dataset, which will enable discovery novel...
Myeloid sarcoma is a neoplastic growth of myeloid blasts that occur in site other than the bone marrow.It has male predilection and median age 56 years.The development megakaryoblastic very rare.Most cases arise from either refractory anemia with excess or chronic idiopathic myelofibrosis as seen one our cases.We report two cases.Case 1 was 1-year-old African American past medical history Down syndrome who brought 8 days fever generalized weakness.Computed tomography-guided fine-needle...
TPS3155 Background: Genomic signatures are revolutionizing the definition, identification, and treatment of breast cancer. To precisely stratify cancers into actionable subgroups, full genome expression data matching clinical must be aggregated a large set. Such set will accelerate research discovery, especially for smaller patient subsets who not as widely represented within current body literature. Methods: FLEX is multicenter, prospective, population-based, observational trial patients...
Abstract Background discussion: Genomic signatures are revolutionizing the definition, identification, and treatment of breast cancer. To precisely stratify cancers into actionable subgroups, full genome (FG) expression data matching clinical must be aggregated a large, real-world dataset. Such dataset will accelerate research discovery, especially for smaller patient subsets that not as widely represented within current body literature. Trial design aims: FLEX is multicenter, prospective,...
Abstract Background: Genomic expression profiles have enabled the classification of breast cancers into molecular subtypes and provide prognostic information about metastatic potential tumor, both which implications for personalized treatment cancer beyond clinical pathological features. However, to precisely stratify tumors actionable subgroups, full genome data should be combined with comprehensive information. The FLEX Registry aims aggregate a large, real-world dataset, will enable...
Abstract Introduction: Early lymph node (LN) metastasis often precedes systemic and corresponds with a 35% decrease in 10-year survival compared to patients without LN metastasis. Understanding biologic pathways involved early could identify promising drug targets for early-stage breast cancer (EBC) treatment. While tumor size modestly correlates the probability of clinical or occult axillary metastases, small T1 tumors are found have while many large T3 negative. We evidence (pT2-3N0)...
Abstract Introduction: Young women with estrogen receptor (ER)-positive early-stage breast cancer (EBC) frequently present larger, higher-grade, more aggressive tumors, lower ER expression than older women. Post-hoc analyses within the MINDACT and TAILORx cohorts reported that aged 40-50 ER+ EBC exhibited a chemotherapy benefit independent of genomic risk compared to > 50, possibly due chemotherapy-induced ovarian suppression (CIOS). However, < 40 years, who seldom develop...
Abstract Background: Genomic signatures provide prognostic information such as tumor metastatic potential, outperforming gained from clinicopathologic factors alone, which has transformed personalized treatment of early breast cancer. Together, whole genome expression data can accurately stratify tumors into clinically actionable molecular subtypes. The FLEX study (NCT03053193) is a large, real-world dataset, combining with annotated data, to accelerate research and discovery subgroups in...
Abstract Background: Coronavirus disease 2019 (COVID-19) resulted in a global pandemic, which led to deferral of surgeries for early stage breast cancer during March - June 2020. Institutional guidelines were developed use neoadjuvant endocrine therapy (NET) as bridge surgery. As follow up initial data presented at SABCS 2020 demonstrating patient acceptance NET, the present study provides results from survey explored psychosocial factors associated with medication compliance. Objective:...
556 Background: Genomic tests, such as MammaPrint (MP) and Oncotype DX Breast Recurrence Score (RS), assess risk of recurrence in patients with early breast cancer (EBC). Using both assays may yield discordant results which leads to uncertainty treatment recommendations. The differ technology genes analyzed. RS relies on RT-PCR query 16 cancer-related 5 controls. MP uses a microarray 70 465 normalization Here we explore the genetic basis for discordance by using FLEX whole transcriptome...
Abstract Background/Objective: Breast cancer incidence in Asian populations has increased recent years, and variation prognosis tumor subtypes indicates that further study is warranted to characterize these differences identify actionable targets. Patients of ancestry are underrepresented US registries, few studies have characterized molecular profiles for patients. In the current analysis, we assess clinical, pathological, from self-reported breast patients (AS), comparison with age-matched...